World Genetically Modified Organism, Gmo: Transgene SA – Product Pipeline Review – H2 2011

• Publication date: June 2012
• Report size: 84 pages

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Transgene SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Transgene SA and market -specific third party sources, put together by Global...

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Transgene SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Transgene SA and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Transgene SA - Brief Transgene SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Transgene SA human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Transgene SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Transgene SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Transgene SA’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Transgene SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Transgene SA’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Transgene SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Transgene SA and identify potential opportunities in those areas.

Genetically Modified Organism, GMO Industry

Table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 6
Transgene SA Snapshot 7
Transgene SA Overview 7
Key Information 7
Key Facts 7
Transgene SA – Research and Development Overview 8
Key Therapeutic Areas 8
Transgene SA – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Transgene SA – Pipeline Products Glance 14
Transgene SA – Late Stage Pipeline 14
Phase III Products/Combination Treatment Modalities 14
Transgene SA Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Transgene SA–Early Stage Pipeline Products 17
Pre-Clinical Products/Combination Treatment Modalities 17
Transgene SA – Drug Profiles 18
TG 3003 18
TG4001 19
TG4010 20
TG4023 21
TG4023 + Flucytosine 22
TG4040 23
TG4040 + Pegylated Interferon Alfa-2a + Ribavirin 24
TG6002 26
Transgene SA – Pipeline Analysis 27
Transgene SA – Pipeline Products by Therapeutic Class 27
Transgene SA - Pipeline Products By Target 29
Transgene SA – Pipeline Products by Route of Administration 31
Transgene SA – Pipeline Products by Molecule Type 32
Transgene SA – Recent Pipeline Updates 33
Transgene SA - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
TG1042 37
TG4010 37
Transgene SA – Operations and Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
July 12, 2010: Transgene Opens First Clinical Site For Phase II Trial Of TG4040 For Treatment Of Chronic Hepatitis C 45
November 07, 2011: Transgene And Jennerex Announce Final Data At AASLD From JX594/TG6006 Randomized Phase II Clinical Trial Showing Statistically Significant Survival Benefit In Patients With Advanced Liver Cancer 49
November 07, 2011: Transgene's Therapeutic HCV Vaccine TG4040 Combined With Commonly Used Treatment Achieves Substantial Viral Suppression In Randomized Phase II Trial 50
September 01, 2010: Transgene Receives Positive EMA Scientific Advice For Phase IIb/III Trial Of TG4010 For Treatment Of Non-Small Cell Lung Cancer 55
Financial Deals Landscape 57
Transgene SA, Merger and Acquisition Deal Summary 57
Transgene SA, Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 58
Venture Financing 58
Jenrin Discovery Secures US$ 3 Mln In Financing 58
Jenrin Discovery Secures Seed Financing 59
Partnerships 60
Innate Pharma And Transgene Form Platine Pharma Services 60
Transgene Concludes a new deal With Beckman Coulter 61
Transgene Enters Into Collaboration With Ventana Medical Systems 62
Tianjin Tasly Forms Joint Venture With Transgene 63
Transgene Enters Into Collaboration Agreement With National Cancer Institute 64
Licensing Agreements 65
ISA Pharmaceuticals Enters Into Licensing Agreement With Transgene 65
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 66
Jennerex Enters Into Licensing Agreement With Transgene For JX-594 68
Transgene Enters Into Option Licensing Agreement With November artis 70
Crucell Enters Into Licensing Agreement With Transgene 72
Roche Enters Into Licensing Agreement With Transgene 73
Virax Holdings Enters Into Licensing Agreement With Transgene 75
Equity Offering 76
Transgene Completes Rights Offering For US$ 228 Mln 76
Transgene Completes Public Offering Of US$ 134 Mln 78
Transgene Raises US$ 18 Mln From Exercise Of Warrants 80
Transgene Raises US$ 4 Mln From Exercise Of Warrants 82
Transgene Completes Public Offering Of US$ 42 Mln 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 85
Contact Us 85
Disclaimer 85

List of Tables

Transgene SA – Pipeline by Therapy Area and Indication, H2 2011 9
Transgene SA – Pipeline by Stage of Development, H2 2011 11
Transgene SA – Monotherapy Products in Pipeline, H2 2011 12
Transgene SA – Combination Treatment Modalities in Pipeline, H2 2011 13
Transgene SA – Phase III, H2 2011 14
Transgene SA - Phase II, H2 2011 15
Transgene SA - Phase I, H2 2011 16
Transgene SA - Pipeline By Therapeutic Class, H2 2011 28
Transgene SA - Pipeline By Target, H2 2011 30
Transgene SA – Pipeline By Route of Administration, H2 2011 31
Transgene SA – Pipeline By Molecule Type, H2 2011 32
Transgene SA – Recent Pipeline Updates, H2 2011 33
Transgene SA - Discontinued Pipeline Products, 2010 37
Transgene SA, Subsidiaries 38
Transgene SA, Merger and Acquisition Deal Summary 57
Jenrin Discovery Secures US$ 3 Mln In Financing 58
Jenrin Discovery Secures Seed Financing 59
Innate Pharma And Transgene Form Platine Pharma Services 60
Transgene Concludes a new deal With Beckman Coulter 61
Transgene Enters Into Collaboration With Ventana Medical Systems 62
Tianjin Tasly Forms Joint Venture With Transgene 63
Transgene Enters Into Collaboration Agreement With National Cancer Institute 64
ISA Pharmaceuticals Enters Into Licensing Agreement With Transgene 65
Virax Holdings Enters Into Licensing Agreement With Transgene For Skin Cancer Drug 66
Jennerex Enters Into Licensing Agreement With Transgene For JX-594 68
Transgene Enters Into Option Licensing Agreement With November artis 70
Crucell Enters Into Licensing Agreement With Transgene 72
Roche Enters Into Licensing Agreement With Transgene 73
Virax Holdings Enters Into Licensing Agreement With Transgene 75
Transgene Completes Rights Offering For US$ 228 Mln 76
Transgene Completes Public Offering Of US$ 134 Mln 78
Transgene Raises US$ 18 Mln From Exercise Of Warrants 80
Transgene Raises US$ 4 Mln From Exercise Of Warrants 82
Transgene Completes Public Offering Of US$ 42 Mln 83

List of Figures

Transgene SA – Pipeline by Therapy Area and Indication, H2 2011 9
Transgene SA – Pipeline by Stage of Development, H2 2011 11
Transgene SA – Monotherapy Products in Pipeline, H2 2011 12
Transgene SA – Combination Treatment Modalities in Pipeline, H2 2011 13
Transgene SA – Pipeline By Therapeutic Class, H2 2011 27
Transgene SA - Pipeline By Target, H2 2011 29
Transgene SA – Pipeline By Route of Administration, H2 2011 31
Transgene SA – Pipeline By Molecule Type, H2 2011 32